Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.
The objective of this study was to track the evolution of sequence changes in both the heptad region 1 (HR1) and HR2 domains of gp41 associated with resistance to enfuvirtide (ENF) in a patient cohort receiving long-term ENF treatment. We studied 17 highly antiretroviral agent-experienced patients receiving long-term ENF treatment with virological rebound or a lack of suppression. Sixty-two samples obtained after between 5 and 107 weeks of ENF therapy were analyzed. Baseline samples from 15 of these 17 patients were available for analysis. Viruses from five samples from four patients were also sequenced after the cessation of ENF therapy. Drug susceptibilities were assessed by a pseudotype virus reporter assay. We identified HR1 and HR2 sequence changes over time in relation to the baseline sequences. Mutations in HR1 (amino acids 36 to 45) were noted in all cases, including previously unreported changes N42Q/H and N43Q. In addition to a range of HR2 sequence changes at polymorphic sites, isolates from 6 of 17 (35%) patients developed an S138A substitution in the HR2 domain at least 8 weeks after the start of ENF treatment and also subsequent to the first emergence of HR1 mutations. In most, but not all, cases the S138A mutation accompanied HR1 mutations at position 43. Molecular modeling demonstrates the close proximity of S138A with amino acids 40 and 45 in HR1. Of note, isolates in samples available from four patients demonstrated the loss of both the HR1 and the S138A HR2 mutations following the cessation of therapy. We show that the S138A HR2 mutation increased the level of resistance by approximately threefold over that conferred by the HR1 mutation N43D. Continual evolution of HR1 in the domain from amino acids 36 to 45 was observed during long-term ENF therapy. We have identified, for the first time, an ENF resistance-associated HR2 mutation, S138A, which appeared in isolates from 6 of 17 patients with virological failure and demonstrated its potential to contribute to drug resistance. We propose that this represents a possible secondary and/or compensatory mutation, particularly when it coexists with mutations at position 43 in HR-1.
Xu
L
L
Health Protection Agency Antiviral Suspectibility Reference Unit, Birmingham, UK.
Pozniak
A
A
Wildfire
A
A
Stanfield-Oakley
S A
SA
Mosier
S M
SM
Ratcliffe
D
D
Workman
J
J
Joall
A
A
Myers
R
R
Smit
E
E
Cane
P A
PA
Greenberg
M L
ML
Pillay
D
D
D000595:Amino Acid Sequence; D024882:Drug Resistance, Viral; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000737:chemistry* / Q000235:genetics / Q000494:pharmacology*; D023581:HIV Fusion Inhibitors / Q000494:pharmacology*; D008969:Molecular Sequence Data; D009154:Mutation; D010446:Peptide Fragments / Q000494:pharmacology*; D020449:Repetitive Sequences, Amino Acid
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide
Protein Sci. 1994 May;3(5):717-29
8061602
AIDS. 2001 May 4;15(7):935-6
11399967
J Virol. 1995 Jun;69(6):3771-7
7538176
AIDS Res Hum Retroviruses. 1995 Mar;11(3):323-5
7786578
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):13-20
8552589
J Biol Chem. 2001 Aug 3;276(31):29485-9
11418583
J Virol. 2001 Sep;75(18):8605-14
11507206
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
12019106
AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):685-93
12167274
AIDS. 2002 Aug 16;16(12):1603-8
12172081
AIDS. 2002 Aug 16;16(12):1684-6
12172092
AIDS. 2002 Sep 27;16(14):1959-61
12351957
N Engl J Med. 2003 May 29;348(22):2175-85
12637625
N Engl J Med. 2003 May 29;348(22):2186-95
12773645
J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):134-9
12794544
AIDS. 2004 Sep 3;18(13):1787-94
15316339
J Mol Biol. 1975 Oct 25;98(2):293-304
1195389
AIDS Res Hum Retroviruses. 1989 Aug;5(4):431-40
2788443
J Virol. 1993 May;67(5):2747-55
8474172
Nature. 1993 Sep 9;365(6442):113
8371754
AIDS Res Hum Retroviruses. 1993 Nov;9(11):1051-3
8312047
Cell. 1997 Apr 18;89(2):263-73
9108481
Nature. 1997 May 22;387(6631):426-30
9163431
J Virol. 1998 Feb;72(2):986-93
9444991
Cell. 1998 May 29;93(5):681-4
9630213
Nat Med. 1998 Nov;4(11):1302-7
9809555
Mol Membr Biol. 1999 Jan-Mar;16(1):3-9
10332732
J Gen Virol. 1990 Dec;71 ( Pt 12):3075-80
2177097
J Virol. 1991 Apr;65(4):2119-23
2002555
J Clin Microbiol. 2000 Feb;38(2):773-80
10655384
J Mol Biol. 2000 Sep 15;302(2):359-75
10970739
J Virol. 2000 Dec;74(24):11858-72
11090186
Science. 2001 Feb 2;291(5505):884-8
11229405
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4
7937889